New cancer clinical trial: The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Published on: December 27, 2017 at 10:00AM
Conditions:   Malignancies;   Stomach Cancer;   Non-small Cell Lung Cancer;   Esophageal Cancer;   Breast Cancer;   Ovary Cancer;   Cervical Cancer
Intervention:   Drug: Apatinib
Sponsor:   Shandong Cancer Hospital and Institute
Recruiting
http://ift.tt/2lk0kKA